Oxford University Coronavirus Vaccine Trials Will Begin This Week


A COVID-19 vaccine developed at the University of Oxford will be tested on humans in the UK starting Thursday this week.

Secretary of Health Matt Hancock said today that he was “throwing everything at Britain’s attempt” to develop the world’s first vaccine.

The government will provide scientists with an additional £ 20 million to aid them in their trials, Hancock said, as well as an additional £ 22.5 million for a project at Imperial College London.

The Oxford vaccine, known as ChAdOx1 nCoV-19, will be tested on up to 510 people aged 18 to 55 in collaboration with Southampton University Hospital.

It is the first vaccine manufactured in Britain to be tested in the real world and carries with it enormous hopes that it will provide a key to break the lock and ban COVID-19.

The virus has now infected more than 125,000 people and killed 17,339 people in the United Kingdom, and the United Kingdom is poised to become one of the most affected countries in the world.

Hancock said that vaccine development is an “uncertain science” that usually takes years, but that manufacturing capacity will be increased in case the vaccine is successful and could be extended to the public.

Speaking at today’s Coronavirus briefing in Downing Street, the Secretary of Health said, “In the long run, the best way to beat the coronavirus is to use a vaccine.

“After all, this is a new disease. It’s an uncertain science, but I’m sure we’ll do our best to develop a vaccine.

“The United Kingdom is at the forefront of a global effort. We have invested more money than any other country in global vaccine research and, for all the efforts in the world, two of the main vaccine developments are happening here at home in Oxford and Imperial. [College London].

“These two promising projects are progressing quickly and I have told the scientists running them that we will do everything in our power to support them. “

He has pledged a total of £ 44.5 million to the Oxford and London projects to allow scientists to continue testing and using the vaccine in humans.

The jab is based on an adenovirus, which is the type that causes the common cold, which has been taken from chimpanzees and damaged so that it cannot make humans sick.

The virus has been genetically engineered to make “cutting edge” proteins found outside of COVID-19 viruses and is essential for its ability to infect humans.

By injecting these proteins into the body but without the rest of the coronavirus, scientists hope to train the immune system to recognize these proteins as an invader that carries the disease and how to attack it.

If successful, it means that a vaccinated person will not get sick if they get the real coronavirus because their body has already learned to attack the proteins that are found outside of it. As a result, the immune system can theoretically destroy it before it can cause symptoms.

Hancock said, “The team accelerated this testing process, in collaboration with the regulator, the MHRA, which was absolutely brilliant.

“And therefore, I can announce that the vaccine from the Oxford project will be tested in people starting this Thursday.

“Normally reaching this stage would take years and I am very proud of the work accomplished so far. “


Please enter your comment!
Please enter your name here